SAI PARENTERALS

Date: 11.08.2026

To

The Manager **BSE Limited** **P. J. Towers, Dalal Street** **Mumbai-400001** **(BSE Scrip Code: 544742)**	The Manager **NSE Limited** **Exchange Plaza, Bandra Kurla Complex,** **Bandra (E), Mumbai- 400051.** **(NSE Symbol: SAIPARENT)**

Unit: Sai Parenteral's Limited

Sub: Outcome of Board Meeting held on Tuesday, 11th August, 2026

***

With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of Sai Parenteral's Limited held on Tuesday, the 11th day of August, 2026 at 11:00 a.m. at the Registered Office of the Company considered and approved the following:

1. Un-audited financial results (Standalone and Consolidated) for the quarter ended June 30, 2026.
2. Limited Review Report (Standalone and Consolidated) for the quarter ended June 30, 2026.
3. Re-appointment of Mr. Anil Kumar Karusala (DIN: 01866646) as Director of the Company, Retiring by rotation. ***(Details are attached as Annexure A)***
4. Re-appointment of Mr. Anil Kumar Karusala (DIN: 01866646) as the Managing Director of the Company for a period of 3 years w.e.f., 01.01.2027, subject to approval of shareholders. ***(Details are attached as Annexure A)***
5. Re-appointment of Mrs. Vijitha Gorrepati (DIN:03492979) as the Whole-time Director of the Company for a period of 3 years w.e.f., 01.01.2027, subject to approval of shareholders. ***(Details are attached as Annexure A)***
6. Appointment of Mr. Kunal Kakumanu (DIN:11281388) as Additional and Executive Director of the Company for a period of 3 years w.e.f., 11.08.2026, subject to approval of shareholders. ***(Details are attached as Annexure A)***
7. Resignation of the Ms. Shivali Aggarwal as Company Secretary & Compliance Officer of the Company on or before 12.10.2026. ***(Details attached as Annexure B) (Resignation Letter enclosed)***
8. Resignation of the Mrs. Aruna Karusala (DIN:01673731) as Non-Executive Director of the Company w.e.f.,11.08.2026. ***(Details attached as Annexure B) (Resignation Letter enclosed)***
9. Variation in the objects and/or terms of utilisation of the IPO proceeds and extension of the time period for utilisation of the IPO proceeds as disclosed in the prospectus dated march 28, 2026, relating to objects (a) Capacity expansion and upgradation of manufacturing facilities and (b) Establishment of a research & development centre, subject to approval of shareholders.

A. Acquisition of Green field Injectables manufacturing plant by acquiring 60% of Equity Shares in Saicriti Pharma Private Limited in lieu of Upgradation of Unit I and Unit II under the Object of Upgradation of Manufacturing Facilities

The amount of Rs. 838.34 million, originally earmarked in the Prospectus towards the upgradation of Unit I and Unit II to achieve compliance with European Union Good Manufacturing Practices (EU-GMP) and thereby cater to the significant demand for its injectable products in international markets, shall now be utilised towards the acquisition of 60% of the equity shares of Saicriti Pharma Private Limited, which is developing a **state-of-the-art critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad, the development of which entails a total estimated cost of Rs. 2,149.60 million**. The proposed acquisition will enable the Company to achieve the same strategic objectives through an alternative implementation mechanism. ***(Brief Details attached as Annexure C)***

B. Acquisition of existing R& Facility by acquiring 60% of the Equity Shares in Prathyak Laboratories Private Limited as an alternative to the establishment of the proposed Research & Development Centre

The amount of Rs.180.23 million originally earmarked for establishment of a new Research & Development Centre shall now be utilised towards acquisition of a 60% equity shares in Prathyak Laboratories Private Limited. Instead of establishing a greenfield R&D facility, the Company proposes to acquire an established pharmaceutical research and development platform, which is expected to achieve the same strategic objectives within a shorter timeframe, with a product portfolio of 124 products development, with lower execution risk and enhanced operational capabilities. ***(Brief Details attached as Annexure C)***

10. Ratification of the Sai Parenterals Limited Employee Stock Option Plan, 2025 (ESOP Scheme-2025), subject to approval of shareholders.

11. Ratification of the extension of benefits of the Sai Parenteral's Limited employee stock option plan 2025 ("ESOP Scheme - 2025") to the subsidiary companies, subject to approval of shareholders.

12. **Incorporation of a New Step-Down Subsidiary of Company in the United States of America:** Incorporation of a New Company in the United States of America as a Wholly Owned Subsidiary of Sai Parenterals Pte. Ltd., Singapore, Wholly Owned Subsidiary of the Company. ***(Brief Details attached as Annexure D)***

13. The Material Related Party Transaction of the Company in respect of the grant of a loan to Sai Singapore Pte. Ltd. for downstream funding to Noumed Pharmaceuticals pty. Limited, Australia, Step down subsidiary, subject to approval of shareholders.
14. The Material Related Party transaction of the Company with Noumed Pharmaceuticals Pty. Limited, step-down subsidiary Company for the FY 2026-27 for sale of goods and/or services, subject to approval of shareholders.

15. Notice of the Annual General Meeting (AGM) the Directors' Report along with the Annexures thereto, the Management Discussion and Analysis Report (MD&A) and the Corporate Governance Report for the Financial Year ended 31.03.2026.
16. Annual General Meeting for the FY 2025-26 is scheduled to be held on Thursday, 10th September, 2026 at 11:00 a.m. through Video Conferencing ("VC")/ other Audio-Visual Means ("OAVM").
17. Reconstitution of the composition of the Committees of the Board with effect from today, 11th August, 2026. ***(Details are attached as Annexure E)***
18. Reconstitution of POSH Committee under the Prevention of Sexual Harassment (POSH) Act. ***(Details are attached as Annexure F)***

The Meeting concluded at 05:00 pm.

This is for the information and records of the Exchanges, please.

Thanking you.
Yours sincerely,
For Sai Parenterals Limited

ANIL KUMAR KARUSALA
Digitally signed by ANIL KUMAR KARUSALA
Date: 2026.08.11 17:58:51 +05'30'

Anil Kumar Karusala
Managing Director
(DIN- 01866646)

Annexure – A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD-2/P/CIR/2026/1 dated January 30, 2026)]

Particulars	**Anil Kumar Karusala (DIN: 01866646)**	**Vijitha Gorrepati (DIN: 03492979)**	**Kunal Kakumanu (DIN: 11281388)**
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Anil Kumar Karusala as Managing Director of the company.	Re-appointment of Mrs. Vijitha Gorrepati as Whole-Time Director of the company.	Appointment of Mr. Kunal Kakumanu as Executive Director of the company.
Date of appointment & Terms of appointment	Re-appointment of Mr. Anil Kumar Karusala (DIN: 01866646) as Managing Director of the Company for a period of three (3) years with effect from 01.01.2027 to 31.12.2029.	Reappointment of Mrs. Vijitha Gorrepati (DIN: 03492979) as Executive Director of the Company for a period of three (3) years with effect from 01.01.2027 to 31.12.2029	Appointment of Mr. Kunal Kakumanu (DIN:11281388) as Executive Director of the Company for a term of Three (3) years w.e.f. 11.08.2026 to 10.08.2029
Brief Profile	Mr. Anil Kumar Karusala is one of the Promoters, Chairman and Managing Director of our Company. He has been on the Board of our Company since November 19, 2021. He received National Award – 2009 in MSME for outstanding entrepreneurship from MSME, Government of India. He also received the Healthcare Iconic Fashion and Awards (HIFAA) recognition as the Best Emerging Entrepreneur in 2025. He has over thirty-one (31) years of experience in the pharmaceutical sector.	Mrs. Vijitha Gorrepati is a Whole Time Director and one of the Promotors of our Company. She has passed bachelor's in commerce from Andhra University. She has been on the Board of Directors of our Company since August 16, 2016. She has over fourteen (14) years of experience in the field of pharmaceutical industry She also serves as an independent director on the board of Phyto Chem (India) Limited.	Mr. Kunal Kakumanu holds a Bachelor of Laws (LL.B.) from the Faculty of Law, University of Delhi, and a Bachelor of Arts (Honours) in Political Science. He has over three (3) years of professional experience in corporate and commercial laws and has represented clients before various judicial and quasi-judicial forums, including the High Courts, NCLT, ITAT and Arbitration Tribunals.
Disclosure of relationships between directors (in case of appointment of a director)	He is Son of Mrs. Aruna Karusala, Director and Mrs. Vijitha Gorrepati, Director of the company.	She is Wife of Mr. Anil Kumar Karusala, Director and Daughter in Law of Mrs. Aruna Karusala, Director of the company.	Grandson of Mrs. Aruna Karusala, Director of the company.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no	NA	NA	NA

SAI PARENTERALS

NSE/CML/2018/24 dated June 20, 2018			

SAI
PARENTERALS

Annexure – B

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026]

Particulars	**Mrs. Aruna Karusala**	**Ms. Shivali Aggarwal**
Reason for change viz. appointment, resignation, removal, death or otherwise	Due to personal reasons.	Due to personal reasons.
Date of appointment & Terms of appointment	Resignation w.e.f. 11th August, 2026.	Resignation w.e.f. on or before 12th October, 2026.
Brief Profile	Not Applicable	Not Applicable
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018	Not Applicable	Not Applicable

Annexure – C

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026]

Name of the Target Entity	M/s. Saicriti Pharma Private Limited	M/s. Prathyak Laboratories Private Limited
Details in brief such as size, turnover etc	Saicriti Pharma Private Limited incorporated on 08.07.2026.	Turn over (Provisional FY 2025-26): 0.61 Lakhs Paid up share capital:2000 Lakhs
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not applicable	Not applicable
Industry to which the entity being acquired belongs	Pharma Sector	Pharma Sector
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Acquisition of 60% of the Equity Shares in Saicriti Pharma Private Limited in lieu of Upgradation of Unit I and Unit II under the Object of Capacity Expansion and Upgradation of Manufacturing Facilities	Acquisition of 60% of the Equity Shares in Prathyak Laboratories Private Limited as an alternative to the establishment of the proposed Research & Development Centre
Brief Details of any governmental or regulatory approvals required for the acquisition	Not required	Not required
Indicative Time period for	Before 30.10.2026	Before 30.10.2026

completion of the acquisition		
Consideration - whether cash consideration or share swap or any other form and details of the same	Cash	Cash
Cost of acquisition and/or the price at which the shares are acquired	83.83 crore (Investment)	15 crore
Percentage of shareholding / control acquired and / or number of shares acquired	Acquisition of 60% of the Equity of Saicriti Pharma Private Limited, subject to approval of shareholders	Acquisition of 60% of the Equity Shares in Prathyak Laboratories Private Limited, subject to approval of shareholders
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Saicriti Pharma Private Limited incorporated on 08.07.2026.	Prathyak Laboratories Private Limited ("Prathyak") incorporated on 16.09.2022. Prathyak has established pharmaceutical R&D organisation at Genome Valley, Hyderabad. Last 3 years turnover: **Financial Year** – **Total Income (In Lakhs)** 2025-26 – 0.61 2024-25 – 7.46 2023-24 – NIL

Annexure – D

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026]

name of the entity, date & country of incorporation, etc.;	Incorporation of a New Company in the United States of America as a Wholly Owned Subsidiary of Sai Parenterals Pte. Ltd., Singapore, Wholly Owned Subsidiary of the Company.
Name of holding company of the incorporated company and relation with the listed entity	Sai Parenterals Pte. Ltd., Singapore, Wholly Owned Subsidiary of the Company.
Industry to which the entity being incorporated belongs	Pharma Sector
Brief background about the entity incorporated in terms of products / line of business	Pharma Sector
Brief Details of any governmental or regulatory approvals required for the acquisition	Not applicable
Nature of consideration - whether cash consideration or share swap and details of the same	Cash
Cost of subscription / price at which the shares are subscribed	Under the process of Incorporation
Percentage of shareholding / control by the listed entity and / or number of shares allotted	100%

SAI PARENTERALS

Annexure – E

RECONSTITUTION OF COMMITTEES

Nomination and Remuneration Committee:

S. No	Name	Designation	Category
1.	Bhagyashri Dharmasa Zad	Non-Executive Independent Director	Chairman
2.	Dr. Seeta Ram Anjaneyulu Gorantla	Non-Executive Independent Director	Member
3.	Kalidindi V Raju	Non-Executive Independent Director	Member

Stakeholders Relationship Committee:

S. No	Name	Designation	Category
1.	Dr. Seeta Ram Anjaneyulu Gorantla	Non-Executive Independent Director	Chairman
2.	Bhagyashri Dharmasa Zad	Non-Executive Independent Director	Member
3.	Kalidindi V Raju	Non-Executive Independent Director	Member

Annexure – F

CONSTITUTION OF POSH COMMITTEE UNDER THE PREVENTION OF SEXUAL HARASSMENT (POSH) ACT

S No.	Name of the Committee Members	Designation
1.	Mrs. Vijitha Gorrepati	Presiding Officer
2.	Mr. Kunal Kakumanu	Member
3.	Mrs. Sujitha Ravoori	External Member
4.	Mrs. Jalaja	Member

SAI PARENTERAL'S LIMITED

Regd.Off. : PLOT NO 39, 5TH FLOOR LAVANYA ARCADE JAYABHERI ENCLAVE, GACHIBOWLI , Seri Lingampally, Telangana, India - 500032., Phone: +91 7997991301

CIN: U24231TG2001PLC036043, Web: www.saiparenterals.com, Email: CS@saiparenterals.com

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30th JUNE, 2026

(₹ in Millions)

Sr. No.	Particulars	Quarter Ended			Financial Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
I	**Income**				
	a. Revenue from Operations	527.79	567.94	192.00	1622.52
	b. Other income	34.14	1.24	12.42	27.40
	Total Income	**561.92**	**569.18**	**204.42**	**1649.93**
II	**Expenses**				
	a. Cost of materials consumed	400.49	268.37	61.30	1058.92
	b. Change in inventories of Finished Goods, WIP and Stock-in-Trade	(59.48)	105.84	45.62	(16.91)
	c. Employees benefits expense	33.40	45.01	27.52	142.99
	d. Finance costs	35.74	34.16	17.58	87.70
	e. Depreciation and amortisation expense	13.63	15.29	13.18	57.83
	f. Other Expenses	19.84	16.46	27.30	131.72
	Total Expenses	**443.62**	**485.13**	**192.50**	**1462.24**
III	**Profit/(Loss) before Exceptional Items & Tax (I-II)**	**118.30**	**84.05**	11.92	**187.69**
IV	Exceptional Items (Refer Note no. 3)				
V	**Profit/(Loss) before Tax (III-IV)**	**118.30**	**84.05**	**11.92**	**187.69**
VI	**Tax expense:**				
	Current tax	25.81	1.62	4.12	29.73
	Deferred tax	3.74	(17.06)	(0.45)	(9.81)
	Earlier Years				
	Total Tax Expenses	**29.55**	**(15.44)**	**3.67**	**19.92**
VII	**Profit/(Loss) after tax (V-VI)**	**88.75**	**99.49**	**8.25**	**167.77**
VIII	**Other Comprehensive Income/(Loss)**				
A.(i)	Items that will not be reclassified to profit or loss	0.00	0.21	0.00	0.83
(ii)	Income Tax on Items that will not be reclassified to profit or loss				
B.(i)	Items that will be reclassified to profit or loss				
(ii)	Income Tax on Items that will be reclassified to profit or loss				
	Total Other Comprehensive Income/(Loss) (Net of Tax)	**-**	**0.21**	**-**	**0.83**
IX	**Total Comprehensive Income for the period (VII+VIII)**	**88.75**	**99.69**	**8.25**	**168.60**
X	Paid-up Equity Share Capital (Face Value of ₹ 5 per Share)	220.90	220.90	133.09	220.90
XI	Other Equity				4648.94
XII	Earning per Equity Share (Not Annualised):				
	(1) Basic EPS before exceptional items	2.01	3.04	0.31	5.13
	(2) Basic EPS after exceptional items	2.01	3.04	0.31	5.13
	(3) Diluted EPS before exceptional items	2.01	3.04	0.31	5.13
	(4) Diluted EPS after exceptional items	2.01	3.04	0.31	5.13

SAI PARENTERALS LIMITED HYDERABAD

Notes:-

1 The above unaudited standalone financial results for the quarter and period ended 30 th June, 2026 have been prepared in accordance wit Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and applicable India Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. The financia results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 11 , 2026. . The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid financial results and have issued an unmodified conclusion thereon.

2 The Earnings Per Share (EPS) for the quarters ended 30 June 2026, 31 March 2026, and 30 June 2025 has not been annualised, as the amounts presented relate to the respective quarterly periods.

3 The Company's equity shares were listed on the National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") with effect from 2 April 2026. Accordingly, the Company was not required to prepare or publish quarterly financial results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30 June 2025. However, the financial information for the quarter ended 30 June 2025 has been presented as unaudited comparative information in these financial results to facilitate comparability.

4 Based on the management approach as defined in Ind AS 108 – Operating Segments, the Chief Operating Decision Maker (CODM) evaluates the Company's performance and allocates resources based on an analysis of various performance indicators of business segment(s) in which the Company operates. The Company is primarily engaged in the business of branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for the domestic and international markets, which the management and CODM recognize as the sole reportable segment. Accordingly, disclosure of segment-wise information is not required and hence has not been provided.

5 There are no exceptional and/or extraordinary items reported during the quarter and period ended 30th June , 2026.

SAI PARENTERALS LIMITED
HYDERABAD

Date : 11 August, 2026
Place : Hyderabad

Anil Kumar Karusala
Managing Director
DIN: 01866646

SAI PARENTERAL'S LIMITED

Regd.Off. : PLOT NO 39, 5TH FLOOR LAVANYA ARCADE JAYABHERI ENCLAVE, GACHIBOWLI , Seri Lingampally, Telangana, India - 500032., Phone: +91 7997991301

CIN: U24231TG2001PLC036043, Web: www.saiparenterals.com, Email: CS@saiparenterals.com

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30th JUNE, 2026

(₹ in Millions)

Sr. No.	Particulars	Quarter Ended			Financial Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
I	**Income**				
	a. Revenue from Operations	1786.72	1979.28	333.91	3809.98
	b. Other income	37.41	28.82	11.74	85.20
	Total Income	**1824.13**	**2008.09**	**345.64**	**3895.18**
II	**Expenses**				
	a. Cost of materials consumed	1161.23	1141.44	167.60	2381.12
	b. Change in inventories of Finished Goods, WIP and Stock-in-Trade	(98.97)	101.52	51.02	41.11
	c. Employees benefits expense	115.42	122.19	32.55	292.81
	d. Finance costs	93.60	83.99	24.64	184.38
	e. Depreciation and amortisation expense	81.10	81.81	14.49	168.52
	f. Other Expenses	373.86	353.20	35.30	707.96
	Total Expenses	**1726.23**	**1884.15**	**325.59**	**3775.90**
III	**Profit/(Loss) before Exceptional Items & Tax (I-II)**	97.90	123.94	20.05	119.28
IV	Exceptional Items				
V	**Profit/(Loss) before Tax (III-IV)**	**97.90**	**123.94**	**20.05**	**119.28**
VI	**Tax expense:**				
	Current tax	41.72	11.85	6.35	49.34
	Deferred tax	(23.05)	(19.48)	(0.45)	(72.65)
	Earlier Years				
	Total Tax Expenses	**18.67**	**(7.62)**	**5.90**	**(23.31)**
VII	**Profit/(Loss) after tax (V-VI)**	**79.23**	**131.57**	**14.15**	**142.59**
VIII	Profit/(Loss) from discountinued operations				
IX	Tax expenses from discountinued operations				
X	**Profit from discountinued operations (after tax) (VIII-IX)**				
XI	**Other Comprehensive Income/(Loss)**				
A.(i)	Items that will not be reclassified to profit or loss	0.00	0.26	0.00	1.06
(ii)	Income Tax on Items that will not be reclassified to profit or loss				
B.(i)	Items that will be reclassified to profit or loss				
(ii)	Income Tax on Items that will be reclassified to profit or loss				
	Total Other Comprehensive Income/(Loss) (Net of Tax)	0.00	0.26	0.00	1.06
XII	**Total Comprehensive Income for the period (VII+VIII)**	**79.23**	**131.83**	**14.15**	**143.65**
XIII	Paid-up Equity Share Capital (Face Value of ₹ 5 per Share)	220.90	220.90	133.09	220.90
XIV	Other Equity				4686.83
XV	Earning per Equity Share (Refer Note no. 36):				
	(1) Basic EPS before exceptional items	1.79	4.02	0.11	4.36
	(2) Basic EPS after exceptional items	1.79	4.02	0.11	4.36
	(3) Diluted EPS before exceptional items	1.79	4.02	0.11	4.36
	(4) Diluted EPS after exceptional items	1.79	4.02	0.11	4.36

SAI PARENTERALS LIMITED HYDERABAD

Notes:-

1 The above unaudited standalone financial results for the quarter and period ended 30 th June, 2026 have been prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. The financial results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 11 , 2026. . The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid financial results and have issued an unmodified conclusion thereon.

2 The Earnings Per Share (EPS) for the quarters ended 30 June 2026, 31 March 2026, and 30 June 2025 has not been annualised, as the amounts presented relate to the respective quarterly periods.

3 The Company's equity shares were listed on the National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") with effect from 2 April 2026. Accordingly, the Company was not required to prepare or publish quarterly financial results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30 June 2025. However, the financial information for the quarter ended 30 June 2025 has been presented as unaudited comparative information in these financial results to facilitate comparability.

4 Based on the management approach as defined in Ind AS 108 – Operating Segments, the Chief Operating Decision Maker (CODM) evaluates the Company's performance and allocates resources based on an analysis of various performance indicators of business segment(s) in which the Company operates. The Company is primarily engaged in the business of branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for the domestic and international markets, which the management and CODM recognize as the sole reportable segment. Accordingly, disclosure of segment-wise information is not required and hence has not been provided.

5 There are no exceptional and/or extraordinary items reported during the quarter and period ended 30th June , 2026.

SAA PARENTERALS LIMITED HYDERABAD

Date : 11 August, 2026
Place : Hyderabad

Anil Kumar Karusala
Managing Director
DIN: 01866646

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS OF THE COMPANY PERSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGUALTION 2015

To
The Board of Directors
Sai Parenterals Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sai Parenterals Limited ("the Company") for the quarter ended 30th June 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), consequent to the listing of the equity shares of the Company on the Stock Exchange.

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. The Statement has been prepared in compliance with the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

R KABRA & CO. LLP
904, Sarap Complex, Opp. Navjivan Press, C.U. Shah College Road, Ashram Road, Ahmedabad-380 009
CHARTERED ACCOUNTANTS

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R Kabra & Co. LLP
Chartered Accountants
Firm Registration No:104502W/W100721

Prakash Tekwani
(Partner)
Membership No: 108681
UDIN: 26108681GVCFOE9886

Place: Hyderabad
Dated: 11/08/2026

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY PERSUANT TO THE REGULATION 33 AND 52 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATION 2015

To
The Board of Directors
SAI PARENTERALS LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Sai Parenterals Limited ("the Company" or "the Holding Company") and its subsidiary (together referred to as "the group") as per Annexure-1, for the quarter ended 30th June, 2026 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("IND AS 34"), "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the master Circular No. CIR/CFD/CMD1 /44/2019 dated March 29, 2019, issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

5. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

6. The statement includes the financial results of Noumed Pharmaceuticals Pty Limited (74.64%) and Noumed Pharmaceuticals Limited (74.64%) whose interim financial results for the quarter ended 30th June, 2026, which have been reviewed by the other auditor, whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amount and disclosures included in respect of that subsidiary is based solely on the reports of the other auditor and procedures performed by other auditor with respect to the subsidiary and in addition to that procedures are performed as stated in paragraph 3 above.

904, Sarap Complex, Opp. Navjivan Press, C.U. Shah College Road, Ashram Road, Ahmedabad-380 009
CHARTERED ACCOUNTANTS

7. Based on our review conducted as above and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Listing including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R Kabra & Co. LLP
Chartered Accountants
Firm Registration No. 104502W/W100721

Prakash Tekwani
Partner
Membership No.: 108681
UDIN: 26108681LYJSTX1989

R KABRA & CO. LLP
904, Sarap Complex, Opp. Navjivan Press, C.U. Shah College Road, Ashram Road, Ahmedabad-380 009
CHARTERED ACCOUNTANTS

Place: Hyderabad
Date: 11th August, 2026

Annexure-1

As of the date Company has five (5) Subsidiaries, out of which two (2) are step-down subsidiaries the details of which are below:

Indian Subsidiaries

1. Revat Laboratories Private Limited; and
2. SP Analytics Private Limited and

Foreign Subsidiaries

1. Sai Parenterals Pte. Limited

Foreign Step-down Subsidiaries

1. Noumed Pharmaceuticals Pty Limited
2. Noumed Pharmaceuticals Limited

Below are the details of total revenue and his profit/(loss) of our Subsidiaries and step down subsidiaries.

(Rs. In Millions)

Company Name	Total Revenue	Total Profit/(Loss)
Revat Laboratories Private Limited	190.33	50.58
Sai Parenterals Pte. Limited	167.21	10.52
Noumed Pharmaceuticals Pty Limited	1037.09	-89.53
Noumed Pharmaceuticals Limited	95.96	8.52
SP Analytics Private Limited	0	-0.50

R. KABRA & CO. LLP
904, Sarap Complex, Opp. Navjivan Press, C.U. Shah College Road, Ashram Road, Ahmedabad-380 009
CHARTERED ACCOUNTANTS

Date: 11th August, 2026

To

The Chairman & Managing Director
Sai Parenteral's Limited
5th floor, Plot No. 39 Jayabheri Enclave, Gachibowli
Hyderabad, Telangana, 500032

Sub: Resignation from the designation of Company Secretary and Compliance Officer (KMP), Legal & Secretarial Department (KMP) of Sai Parenteral's Limited.

Dear Sir,

I am writing to tender my resignation from the designation of Company Secretary and Compliance Officer (KMP) of Sai Parenteral's Limited ("Company") on or before 12th October, 2026.

This has been a very difficult decision to make as I have been very happy throughout my employment with the Company, but I have been stuck with a personal situation which needs my full time presence at my place. Therefore, I request you to kindly accept my resignation and file the required E-form with Ministry of Corporate Affairs.

Yours sincerely,

Shivali Aggarwal
Company Secretary and Compliance Officer
Legal & Secretarial Department

Date: 11th August, 2026

To

The Chairman & Managing Director
Sai Parenteral's Limited
5th floor, Plot No. 39 Jayabheri Enclave, Gachibowli
Hyderabad, Telangana, 500032

Sub: Resignation as Director of Sai Parenteral's Limited.

Dear Sir,

I Aruna Karusala, writing to tender my resignation from the designation of Director of Sai Parenteral's Limited ("Company") with immediate effect i.e., 11th August, 2026.

This has been a very difficult decision to make as I have been very happy throughout my employment with the Company, but I have been stuck with a personal situation which needs my full time presence at my place.

Yours sincerely,

K. Aruna.

Aruna Karusala
Director
DIN: 01673731